The university of Besancon is making a Car-T cell therapy for CML. They still need 25000 euros.
"Because CML is a model immune system-sensitive disease, we hypothesize that chimeric antigen receptor (CAR) T cells targeting interleukin-1 receptorassociated protein (IL-1RAP) in quiescent CML stem cells may offer an opportunity for a permanent cure."
The preclinical work can be found here:
I have read the paper with great interest, except that I think that a Car NK cell therapy is more successful because it has a lower risk of graft versus host disease. What they want to do with this, is take t cells from a donor, because your own immune cells are weakened in CML. Because they talk about a "allogenic donor-derived CART cell immunotherapy".
What I understand from the preclinical work, is that not only the stem cells have the IL1RAP receptor, but also a lot of derived cells. So you can theoretically eradicate more cells than the stem cell compartment. IL1RAP is also expressed on the monocyte compartment, but they do not see this as a major clinical problem. They explain this in the preclincal work. They talk about an eradication rate of 94,77% of leukemic cells (not only stem cells)